AI Summary
- Two case reports describe severe cholinesterase reduction temporally associated with rivastigmine transdermal patch use.
- Marked enzyme decline produced clinically significant cholinergic effects necessitating dose reduction or discontinuation.
- Advocate cholinesterase monitoring, vigilance for interactions and caution in hepatic impairment or frail patients when prescribing rivastigmine patches.
Am J Ther. 2026 Oct 28. doi: 10.1097/MJT.0000000000002254. Online ahead of print.
NO ABSTRACT
PMID:42950131 | DOI:10.1097/MJT.0000000000002254
Share Evidence Blueprint
Save to Google Notes
Search Google Scholar
Save as PDF
⭐ My Revision List
